To the full analysis
M1 Kliniken stock: growth
M12.DEM1 Kliniken reported $403.68M in revenue for fiscal 2025, up 7.4% on the prior year, up 17.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
40.6%
per year from 2013 to 2025, per share 38.2%
Earnings (Annual rate)
55.7%
per year from 2013 to 2025, per share 52.9%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2013 | |
|---|---|---|---|
| Revenue | 17.9% | 26.4% | 40.6% |
| Revenue per share | 18.0% | 23.8% | 38.2% |
| Earnings | 26.5% | 12.8% | 55.7% |
| Earnings per share | 26.3% | 10.5% | 52.9% |
| Free cash flow | 36.7% | no data | no data |
| Free cash flow per share | 36.7% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2013 | $6.74M | $120.78K | −$6.34M |
| 2014 | $25.51M | $5.08M | $848.7K |
| 2015 | $38.7M | $7.35M | −$941.17K |
| 2016 | $39.84M | $5.55M | $7.86M |
| 2017 | $52.3M | $6.4M | −$1.33M |
| 2018 | $72.26M | $7.33M | $847.15K |
| 2019 | $85.56M | $10.78M | −$5.4M |
| 2020 | $176.84M | $7.56M | $8.79M |
| 2021 | $348.62M | $9.87M | $15.87M |
| 2022 | $316.13M | $4.78M | $21.33M |
| 2023 | $350.51M | $11.38M | $7.54M |
| 2024 | $375.85M | $17.75M | $32.74M |
| 2025 | $403.68M | $24.52M | $41.93M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 24 Apr 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.